Clinical trials: Cancer of Esophagus
Esophageal Squamous Cell Carcinoma
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT07700667
- Testing
- SKB500, Tislelizumab, Cisplatin
- Where
- 24 sites in China
- Volunteers
- 120 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Peri Operative Analgesia
ESP Versus TEA for Oeasophagus Cancer Surgery
For esophagectomy, peri-operative continuous thoracic epidural analgesia (TEA) is the standard of care for perioperative pain management.
- Trial name
- ESPOK (NCT05631834)
- Testing
- Thoracic epidurale, Erector spinae block
- Volunteers
- 50 people
- Sponsor
- Vinmec Healthcare System
Esophageal Cancer
Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer
The purpose of this study is determine if performing endobronchial ultrasound (EBUS) in addition to standard endoscopic ultrasound (EUS) can increase the precision and accuracy of staging esophageal cancer in comparison to EUS…
- Trial name
- CT0003 (NCT01038544)
- Testing
- Endoscopic Ultrasound (EUS), Endobronchial Ultrasound (EBUS)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Esophageal Squamous Cell Carcinoma
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal…
- Trial name
- NCT05495152
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 219 people
- Sponsor
- Henan Cancer Hospital
Gastric Neoplasm, Esophageal Neoplasms
Non-curative ESDs: Assessing the Rates and Risk Factors for Residual Neoplasia
Short and long outcomes of ESD are well described, particularly in Eastern series. However, the outcome of non-curative ESDs is scarcely reported in the west (particularly among non-gastric or submucosal lesions).
- Conditions
- Gastric Neoplasm, Esophageal Neoplasms, Colorectal Neoplasms
- Trial name
- NC-ESD (NCT04484311)
- Where
- Portugal
- Volunteers
- 300 people
- Sponsor
- Universidade do Porto
Esophageal Cancer
Morbidity in Open Versus Minimally Invasive Esophagectomy
The MIOMIE trial is a prospective randomized controlled study comparing open and laparoscopic gastric tube formation in Ivor Lewis esophagectomy.
- Trial name
- MIOMIE (NCT03035071)
- Testing
- minimally invasive esophagectomy, open esophagectomy
- Volunteers
- 26 people
- Sponsor
- Austrian Society Of Surgical Oncology
Breast Cancer, Lung Cancer
Intra-individual Comparison of Conventional and Digital PET/CT Scanners
In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Miscellaneous Neoplasm
- Trial name
- NCT03457506
- Testing
- Digital PET/CT scan
- Where
- Netherlands
- Volunteers
- 225 people
- Sponsor
- Isala
Esophageal Cancer
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study
The objective of this clinical trial is to determine whether the addition of immunotherapy combined with chemotherapy before chemoradiotherapy can increase the survival rate of patients with esophageal cancer.
- Trial name
- ESO-Nanjing7 (NCT07306663)
- Testing
- Sintilimab, 3-Weekly Paclitaxel plus Carboplatin (TC) Chemotherapy, Weekly TC Chemotherapy
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma.
- Trial name
- TroFuse-015 (NCT06356311)
- Testing
- Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan
- Where
- 168 sites in United States, Belgium and 22 more
- Volunteers
- 473 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Esophageal Cancer
Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery
Patients on this observation study must have planned treatment regimen with concurrent CRT followed by planned surgery, which is considered as standard of care for their disease.
- Trial name
- NCT03095209
- Testing
- Carboplatin, Paclitaxel, Radiation Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Fox Chase Cancer Center
Esophageal Squamous Cell Carcinoma
Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma
The goal of this multicenter retrospective cohort study is to evaluate the impact of different pathological regression types on survival and recurrence patterns, with a particular focus on ypT0N+ patients in patients with…
- Trial name
- NCT06241079
- Testing
- non-intervention
- Volunteers
- 582 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer
The RESPECT study is intended to prospectively assess the impact of PET/CT on the delineation of target volumes and to estimate the proportion of recurrences that could possibly be prevented by the use of PET/CT-based target…
- Trial name
- RESPECT (NCT01836913)
- Where
- 3 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- University Medical Center Groningen
Barrett's Esophagus, Esophageal Cancer
University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository
Aim 1: To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition.
- Conditions
- Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
- Trial name
- BEECAB (NCT02427269)
- Testing
- Specimen Collection
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Neoplasm
A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to: 1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients, 2.
- Trial name
- NCT00037089
- Testing
- UFT (Tegafur/Uracil)
- Where
- United States
- Sponsor
- Edelman, Martin, M.D.
Thoracic Esophageal Squamous Cell Carcinoma
Improve the Treatment of Thoracic Esophageal Cancer
The purpose of this study is 1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on the staging and prognosis of resectable esophageal cancer, which defined by the International Association of…
- Trial name
- NCT01137123
- Testing
- adjuvant chemotherapy, standard two field Lymphadenectomy, Total two field Lymphadenectomy
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Sun Yat-sen University
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic